Compare metabolites in 2 of these studies:
Study A:   Study B:  

List of Studies ( Metabolite:Ala-Gly-Pro)

Study_idAnalysis_idStudy_titleSourceSpeciesDiseaseInstituteAnalysis Type
ST004290 AN007133 Metabolomics characterisation of Plasmodium falciparum response to plasmepsin V peptidomimetic inhibitors - 5 hour treatment Blood Plasmodium falciparum Malaria Monash University LC-MS
ST004194 AN006966 PfK13-associated artemisinin resistance slows drug activation and enhances antioxidant defence, which can be overcome with sulforaphane Cultured cells Plasmodium falciparum Malaria Monash University LC-MS
ST003521 AN005782 Metabolic Profiling Unveils Enhanced Antibacterial Synergy of Polymyxin B and Teixobactin against Multi-Drug Resistant Acinetobacter baumannii Bacterial cells Acinetobacter baumannii Bacterial infection Monash University LC-MS
ST003521 AN005783 Metabolic Profiling Unveils Enhanced Antibacterial Synergy of Polymyxin B and Teixobactin against Multi-Drug Resistant Acinetobacter baumannii Bacterial cells Acinetobacter baumannii Bacterial infection Monash University LC-MS
ST003160 AN005184 New class of heterospirocyclic compounds present strong and rapid activity against artemisinin- and multidrug-resistant P. falciparum parasites Plasmodium cells Plasmodium falciparum Malaria Monash University LC-MS
ST003144 AN005159 On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity Blood Plasmodium falciparum Malaria Monash University LC-MS
ST003053 AN005006 Providing insight into the mechanism of action of Cationic Lipidated Oligomers (CLOs) using metabolomics Bacterial cells Staphylococcus aureus Bacterial infection Monash University LC-MS
ST003036 AN004977 Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa - Part 2 Bacterial cells Pseudomonas aeruginosa Bacterial infection Monash Institute of Pharmaceutical Sciences LC-MS
ST003024 AN004958 Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa - Part 1 Bacterial cells Pseudomonas aeruginosa Monash Institute of Pharmaceutical Sciences LC-MS
ST002926 AN004798 Multi-“omics” analysis reveals the orphan P. falciparum protein kinase PfPK8 regulates multi-gene family expression Blood Plasmodium falciparum Malaria Monash University LC-MS
ST002792 AN004542 Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as a cross-species strategy to treat malaria Blood Plasmodium falciparum Malaria Monash University LC-MS
ST002309 AN003771 Targeting malaria parasites with novel derivatives of azithromycin Blood Plasmodium falciparum Malaria Monash University LC-MS
ST002108 AN003448 Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 3) Blood Plasmodium falciparum Malaria Monash University LC-MS
ST002107 AN003446 Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 2) Blood Plasmodium falciparum Malaria Monash University LC-MS
ST002106 AN003444 Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 1) Blood Plasmodium falciparum Malaria Monash University LC-MS
ST001788 AN002899 β-Adrenergic regulation of metabolism in macrophages (part-IV) Macrophages Human Monash University LC-MS
ST001549 AN002580 β-Adrenergic regulation of metabolism in macrophages (part-III) Macrophages Human Monash University LC-MS
ST001548 AN002578 β-Adrenergic regulation of metabolism in macrophages (part-II) Macrophages Human Monash University LC-MS
ST001547 AN002576 β-Adrenergic regulation of metabolism in macrophages Macrophages Human Monash University LC-MS
ST001315 AN002189 Retargeting azithromycin-like compounds as antimalarials with dual modality Blood Plasmodium falciparum Malaria Monash University LC-MS
ST001205 AN002006 Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites Cultured cells Human Malaria Monash University LC-MS
ST001205 AN002006 Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites Cultured cells Plasmodium falciparum Malaria Monash University LC-MS
ST001175 AN001950 Multi-omics analysis demonstrates unique mode of action of a potent new antimalarial compound, JPC-3210, against Plasmodium falciparum Plasmodium cells Plasmodium falciparum Malaria Monash University LC-MS
ST001033 AN001694 Determination of mode of action of anti-malalrial drugs using untargeted metabolomics Cultured cells Plasmodium falciparum Malaria Monash University LC-MS
ST000546 AN000832 Multi-omics based identification of specific biochemical changes associated with PfKelch13-mutant artemisinin resistant Plasmodium Cells Plasmodium falciparum Malaria Monash University LC-MS
  logo